References
- Kropeit D, Scheuenpflug J, Erb-Zohar K, Halabi A, Stobernack HP,
Hulskotte EGJ, van Schanke A, Zimmermann H, Rübsamen-Schaeff H.
Pharmacokinetics and safety of the anti-human cytomegalovirus drug
letermovir in subjects with hepatic impairment. Br J Clin
Pharmacol . 2017;83(12):2678-2686.
- Kropeit D, McCormick D, Erb-Zohar K, Moiseev VS, Kobalava ZD,
Stobernack HP, Zimmermann H, Rübsamen-Schaeff H. Pharmacokinetics and
safety of letermovir, a novel anti-human cytomegalovirus drug, in
patients with renal impairment. Br J Clin Pharmacol .
2017;83(9):1944-1953.
- Kobie J, Guo Z, Cho CR, Menzel K, McCrea JB, Blanchard R, Shaw
PMPharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in
Relation to the Pharmacokinetics of Letermovir in Previously Conducted
Clinical Studies. J Clin Pharmacol . 2019;59(9):1236-1243.
- Royston L, Masouridi-Levrat S, Gotta V, Royston E, Pressacco-Brossier
C, Abi Aad Y, Tonoli D, Karmime A, Jayo M, Van Delden C, Lescuyer P,
Pfister M, Chalandon Y, Neofytos D. Therapeutic Drug Monitoring of
Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic
Stem Cell Transplant Recipients. Antimicrob Agents Chemother.2022;;66(8):e0065722.
- Menzel K, Kothare P, McCrea JB, Chu X, Kropeit D. Absorption,
Metabolism, Distribution, and Excretion of Letermovir. Curr Drug
Metab . 2021;22(10):784-794.
- Isberner N, Aghai F, Schirmer D, et al. Determination of Letermovir
Serum Levels Can Be Useful in High-Risk Clinical Settings. J
Pediatric Infect Dis Soc . 2020;9(3):402-403.
- Isberner N, Aghai F, Schirmer D, Kraus S, Grigoleit GU, Klinker H.
Quantification of letermovir in human serum using high-performance
liquid chromatography with diode array detection. J Chromatogr B
Analyt Technol Biomed Life Sci . 2020;1159:122399.
- Isberner N, Aghai F, Schirmer D, Bolz M, Kraus S, Grigoleit GU,
Klinker H. Letermovir exposure in transplant patients with end-stage
renal disease on renal replacement therapy. J Antimicrob
Chemother . 2021;76(12):3322-3325.
- McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F,
Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M.
Pharmacokinetic Drug-Drug Interactions Between Letermovir and the
Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and
Mycophenolate Mofetil. J Clin Pharmacol . 2019;59(10):1331-1339.
- Adedoyin A, Fancourt C, Menzel K, Zhao T, Tomek C, Panebianco D,
McCrea JB, Stoch SA, Iwamoto M. Assessment of Pharmacokinetic
Interaction Between Letermovir and Fluconazole in Healthy
Participants. Clin Pharmacol Drug Dev. 2021;10(2):198-206.
Table I. List of the medications prescribed before the
development of lactic acidosis.
Figure 1. Evolution of lactic acidosis over time.
Figure 2. Pharmacokinetics of letermovir, first sample obtained
one hour before the start of continuous venonevous hemofiltration and 18
hours after the last oral administration.